心臓バイオマーカー(臨床検査、ポイントオブケア検査(POCT)、急性心筋梗塞(AMI)、その他)の世界市場

◆英語タイトル:Cardiac Biomarkers (Clinical Laboratory Testing, Point-of-Care Testing (POCT), Acute myocardial infarction (AMI), etc.) : Global Strategic Business Report
◆商品コード:GIA60044
◆発行会社(調査会社):Global Industry Analysts
◆発行日:2016年4月
◆ページ数:236
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(DRM付き)USD4,500 ⇒換算¥499,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Industry Analysts社の日本における正規販売代理店です。Global Industry Analysts社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、心臓バイオマーカー(臨床検査、ポイントオブケア検査(POCT)、急性心筋梗塞(AMI)、その他)の世界市場について調査・分析し、心臓バイオマーカー(臨床検査、ポイントオブケア検査(POCT)、急性心筋梗塞(AMI)、その他)の世界市場規模、市場動向、市場予測、関連企業情報などをお届けいたします。
【レポートの概要】

This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Thousand by the following Testing Locations: Laboratory Testing, and Point of Care Testing. The Global, US and European markets are further analyzed by the following Test Types: Cardiac Troponin, BNP and NT-proBNP, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 44 companies including many key and niche players such as –
Abbott Diagnostics, Inc.
Alere, Inc.
Beckman Coulter, Inc.
BG Medicine, Inc.
biomérieux SA

【レポートの目次】

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
Cardiac Biomarkers
Testing Location
Laboratory Testing
Point of Care Testing
Types of Cardiac Biomarkers
Cardiac Troponin
Natriuretic Peptides
BNP (B-type Natriuretic Peptide)
NT-proBNP (N-terminal proBNP)
Others
Creatine Kinase-MB (CK-MB)
Myoglobin
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Curtain Raiser
Major Cardiac Markers and their Properties
Current and Future Scenario
North America Corners Biggest Slice, Asia-Pacific to Dictate Market Momentum
Laboratory Testing Remains Gold Standard, POC Testing Rapidly Gains Traction
Analysis by Type of Cardiac Biomarker Assay/Test
Emerging Markets, New Product Introductions Hold Key to Reviving Saturated Cardiac Troponin Assays Market
Competitive Landscape
Intense Competition among Players in the Cardiac Diagnostics Market
Leading Vendors Focus on Curtailing Turnaround Time of POC Cardiac Testing Kits
Cardiac Markers Point-Of-Care Testing (POC) Cardiac Testing Segment: Major Players and their Operating Brands
2. MARKET GROWTH DRIVERS, TRENDS & ISSUES
The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease
Table 1: Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart)
Population Explosion, Ballooning Geriatric Populace, Longer Life Expectancy Contributing to Rising Tide of CVDs
Table 2: Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)
Table 3: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2000, 2011, and 2020 (includes corresponding Graph/Chart)
Table 4: Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart)
Table 5: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013 (includes corresponding Graph/Chart)
Table 6: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
Table 7: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
Cardiac Biomarkers Hold the Key to Timely, Accurate Diagnosis & Prognosis
Commercialization of Novel Biomarkers to Drive Market Growth
Personalized Medicine, Companion Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
Cardiac Biomarkers – a Powerful Tool for Patient Triaging
Cardiac Biomarkers Market Transitions from Mono-Marker to Multi-Marker Assays
Government Support Instrumental for Boosting Market Momentum
Secretoneurin Biomarker – a Potential Game Changer for Diagnosis of Cardiac Arrhythmias
High-Performance Techniques Drive Biomarker Discovery in Cardiology
Biomarkers for Acute Coronary Syndromes (ACS): A Leading Segment
Biomarkers – A Promising Diagnostic Tool for ACS
Biomarker Discovery for ACS to Undergo Significant Changes
Cardiac Biomarker Play Critical Role in Stroke Diagnosis
Cardiac Biomarkers to Find a Place in Neonatal Diagnosis and Treatment
Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market Growth
3. PRODUCT OVERVIEW
Cardiac Biomarkers
Necessity of a Cardiac Marker Assay Test
Cardiac Markers and Myocardial Infarction (MI)
Chain Reaction after an Event of MI
Action Plan after an Event of MI
Protocol for Conducting AMI Markers Tests
Myocardial Infarction Cardiac Biomarkers – Benefits and Limitations
Cardiac Markers and Congestive Heart Failure (Chf)
Key Facts
Types of Cardiac Biomarkers
Major Cardiac Markers and their Properties
Creatine Kinase – The Gold Standard Losing Sheen
Isomers
Kinetics
Purpose of Test and When to Order
Evaluation
Points to remember
Cardiac Troponin
Troponin Tissue-Specific Subtypes
Other Diseases
Uses of Troponin Tests
New Advanced High-sensitivity (Hs) Cardiac Troponin Tests
Myoglobin
Purpose of Test and When to Order
Testing and Evaluation
Points of Caution
Natriuretic Peptides
BNP (B-type Natriuretic Peptide)
NT-proBNP (N-terminal proBNP)
Purpose of Tests and When to Order
Testing and Evaluation
Points to Remember
Introduction of BNP Test and the Changing Market Scenario in the Segment: A Review
Choosing the Right BNP and NT proBNP Assay Kit in the Market
Evolution of BNP and NT proBNP Market
NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function
Other Important Cardiac Biomarkers
Homocysteine
C-Reactive Protein
Plasminogen Activator
D-Dimer
Thrombus Precursor Protein
Biomarker
: An Overview of Clinical Studies
: Overview of Clinical Studies in Cardiovascular Disease Diagnosis
Potential Future Cardiac Biomarkers
Location of Cardiac Biomarker Testing
Laboratory Cardiac Testing
Point-of-Care Cardiac Testing
4. PRODUCT INTRODUCTIONS
Singulex Secures US Patent for Cardiac Troponin I and T Biomarkers for Detecting CVDs
Singulex Wins European Patent for Cardiac Troponin I and T Biomarkers for Detecting Cardiac Damage
Critical Diagnostics Receives China FDA Clearance for Clinical Use of Presage ST2 Assay
Critical Diagnostics Secures CE Mark for Aspect-PLUS ST2 Test
Roche Diagnostics Introduces Improved Cardiac POC Troponin T test for cobas h 232 System
BG Medicine Receives US Patent for
and Cardiac Resynchronization Therapy
Critical Diagnostics Unveils Aspect-LF ST2 Test
Olink Bioscience Unveils Proseek Multiplex CVD I96x96 Protein Biomarker Panel
BG Medicine Gains AHA and ACCF Recognition for
Testing
5. RECENT INDUSTRY ACTIVITY
Eurofins Scientific Completes Takeover of Boston Heart Diagnostics Corp.
Lee Biosolutions Steps Up Investment for Development of High Value Cardiac Markers
MaRS Innovation Enters into Collaboration with Johnson & Johnson Innovation and Janssen
ACS Biomarker BV Establishes Mirnext BV
Critical Diagnostics Releases Results of Study on Cardiac Biomarker ST2
6. FOCUS ON SELECT PLAYERS
Abbott Diagnostics, Inc. (USA)
Alere, Inc. (USA)
Beckman Coulter, Inc. (USA)
BG Medicine, Inc. (USA)
biomérieux SA (France)
Boditech Med Inc. (South Korea)
Labsystems Diagnostics OY (Finland)
LifeSign LLC (USA)
LSI Medience Corporation (Japan)
Ortho-Clinical Diagnostics, Inc. (USA)
Randox Laboratories Ltd. (UK)
Response Biomedical Corp. (Canada)
Roche Diagnostics Corp. (Switzerland)
Siemens Healthcare Diagnostics, Inc. (USA)
Singulex, Inc. (USA)
7. GLOBAL MARKET PERSPECTIVE
Cardiac Biomarkers Testing By Geographic Region
Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 9: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 10: World 14-Year Perspective for Cardiac Biomarkers by Geographic Region – Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 11: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 13: World 14-Year Perspective for Cardiac Biomarkers in Laboratory Testing by Geographic Region – Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Table 14: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 15: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 16: World 14-Year Perspective for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region – Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Market by Assay Test Type
Table 17: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Test Type – Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 18: World Historic Review Analysis for Cardiac Biomarkers by Test Type – Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 19: World 14-Year Perspective for Cardiac Biomarkers by Test Type – Percentage Breakdown of Dollar Revenues for Cardiac Troponin, BNP & NT-proBNP, and Others Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

III. MARKET
1. THE UNITED STATES
A. Market Analysis
Current and Future Analysis
Statistics for Cardiovascular Diseases and Stroke, and Related Risk Factors and Costs in the US
Table 20: Prevalence of Cardiovascular Disease in US Adult Population by Gender and Age (2009-2012): Prevalence Percentage of CVDs for Males and Females of Age Groups - 20-39 Years, 40-59 Years, 60-79 Years, and 80 Years & Above (includes corresponding Graph/Chart)
Table 21: Prevalence of Stroke in US Adult Population by Gender and Age (2009-2012): Prevalence Percentage of CVDs for Males and Females of Age Groups - 20-39 Years, 40-59 Years, 60-79 Years, and 80 Years and Above (includes corresponding Graph/Chart)
Table 22: Prevalence of High Blood Pressure in US Adult Population by Gender and Age (2009-2012): Prevalence Percentage of CVDs for Males and Females of Age Groups - 20-34 Years, 35-44 Years, 45-54 Years, 65-74 Years, and 75 Years & Above (includes corresponding Graph/Chart)
Table 23: Prevalence of Diabetes and Obesity in US Adult Population by Gender (2009-2012): Prevalence Percentage of Physician Diagnosed Diabetes, Undiagnosed Diabetes, and Obesity for Males and Females of Age 20 Years & Above (includes corresponding Graph/Chart)
Table 24: US Total Annual Average Expenditure for Cardiovascular Diseases by Type of CVD (2015): Percentage Breakdown of Expenditure for Heart Disease, Hypertension, Stroke and Other CVDs (includes corresponding Graph/Chart)
Product Introductions & Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Cardiac Biomarkers Testing By Location of Testing
Table 25: The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 26: The US Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 27: The US 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Market by Assay Test Type
Table 28: The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 29: The US Historic Review Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 30: The US 14-Year Perspective for Cardiac Biomarkers by Test Type - Percentage Breakdown of Dollar Revenues for Cardiac Troponin, BNP & NT-proBNP, and Others Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
2. CANADA
A. Market Analysis
Current and Future Analysis
Strategic Corporate Development
Select Key Player
B. Market Analytics
Table 31: Canadian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 32: Canadian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 33: Canadian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
3. JAPAN
A. Market Analysis
Current and Future Analysis
LSI Medience Corporation - A Key Japanese Player
B. Market Analytics
Table 34: Japanese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 35: Japanese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 36: Japanese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4. EUROPE
A. Market Analysis
Current and Future Analysis
Growing Prevalence of Cardiovascular Disease Propels Growth of European Cardiac Biomarkers Market
Cardiac Markers in Primary Care Sector
B. Market Analytics
Table 37: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 38: European Historic Review Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 39: European 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 40: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 41: European Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 42: European 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Market by Assay Test Type
Table 43: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44: European Historic Review Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 45: European 14-Year Perspective for Cardiac Biomarkers by Test Type - Percentage Breakdown of Dollar Revenues for Cardiac Troponin, BNP & NT-proBNP, and Others Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4a. FRANCE
A. Market Analysis
Current and Future Analysis
Select Key Player
B. Market Analytics
Table 46: French Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 47: French Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 48: French 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4b. GERMANY
Market Analysis
Table 49: German Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 50: German Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 51: German 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 52: Italian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 53: Italian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 54: Italian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A. Market Analysis
Current and Future Analysis
Randox Laboratories Ltd. – A Key Player
B. Market Analytics
Table 55: The UK Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 56: The UK Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 57: The UK 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 58: Spanish Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 59: Spanish Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 60: Spanish 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 61: Russian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 62: Russian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 63: Russian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
4g. REST OF EUROPE
A. Market Analysis
Current and Future Analysis
Product Introductions & Approvals
Strategic Corporate Development
Select Key Players
B. Market Analytics
Table 64: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 65: Rest of Europe Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 66: Rest of Europe 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
Market Analysis
Table 67: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 68: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 69: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 70: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 71: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 72: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
5a. CHINA
A. Market Analysis
Current and Future Analysis
Product Introductions & Approval
B. Market Analytics
Table 73: Chinese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 74: Chinese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 75: Chinese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
5b. INDIA
Market Analysis
Table 76: Indian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 77: Indian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 78: Indian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC
A. Market Analysis
Boditech Med Inc. (South Korea) – A Key Player
B. Market Analytics
Table 79: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 80: Rest of Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 81: Rest of Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
6. LATIN AMERICA
Market Analysis
Table 82: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 83: Latin American Historic Review Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 84: Latin American 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for Brazil, and Rest of Latin America Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
Cardiac Biomarkers Testing By Location of Testing
Table 85: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 86: Latin American Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 87: Latin American 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
6a. BRAZIL
Market Analysis
Table 88: Brazilian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 89: Brazilian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 90: Brazilian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
6b. REST OF LATIN-AMERICA
Market Analysis
Table 91: Rest of Latin-America Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 92: Rest of Latin-America Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 93: Rest of Latin-America 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
7. REST OF WORLD
Market Analysis
Table 94: Rest of World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 95: Rest of World Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 96: Rest of World 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 44 (including Divisions/Subsidiaries - 50)
The United States (26)
Canada (3)
Europe (14)
- France (1)
- Germany (1)
- The United Kingdom (3)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (7)

★調査レポート[心臓バイオマーカー(臨床検査、ポイントオブケア検査(POCT)、急性心筋梗塞(AMI)、その他)の世界市場]販売に関する免責事項
★調査レポート[心臓バイオマーカー(臨床検査、ポイントオブケア検査(POCT)、急性心筋梗塞(AMI)、その他)の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆